PRKAA1 and fatty liver disease: The therapeutic effects of EMO are closely associated with the regulation of the ERS-SREBP1c pathway and the activation of the CaMKK-AMPK-mTOR-p70S6K-SREBP1 signaling pathway, which significantly ameliorate hepatic steatosis [127,128].